| answer text |
<p>It remains our objective to negotiate a future relationship with the European Union
to ensure that patients across the United Kingdom continue to have unfettered access
to the medicines and medical products they need at the end of the transition period.</p><p>In
consultation with the devolved administrations and crown dependencies, we are working
with trade bodies, suppliers and the health and care system to implement detailed
plans to help ensure the continued supply of medicines and medical products, including
Enzalutamide, in all scenarios. In the Department’s letter to industry of 3 August,
we asked suppliers to get trader ready, consider alternative routes away from potential
disruption and stockpile medicines that come from or via the EU on UK soil to a target
level of six weeks where this is possible. The letter is available at the following
link:</p><p><a href="https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020"
target="_blank">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020</a></p>
|
|
